Endologix Detour System Granted CMS Transitional Pass-Through Payment

December 27, 2023—Endologix LLC announced that the Centers for Medicare & Medicaid Services (CMS) granted a transitional pass-through (TPT) payment for the company’s Detour system, effective January 1, 2024. The TPT will provide hospitals with additional device reimbursement when the Detour system is used for eligible cases in the hospital outpatient setting.

Details on the TPT, code C1604, can be found in the January 2024 update of the hospital outpatient prospective payment system, which is accessible on the CMS website (here) and the Endologix website (here).

In June 2023, Endologix announced FDA approval for the Detour system to treat patients with complex peripheral arterial disease via percutaneous transmural arterial bypass (PTAB). The company commenced a targeted market release of the device in July.

In September 2023, the company announced that the CMS granted a new technology add-on payment for the Detour system for PTAB as part of the CMS FY2024 hospital inpatient prospective payment system, providing hospitals with additional device reimbursement when the Detour system is used for eligible cases in the hospital inpatient setting.

According to the company, the Detour system’s is indicated for percutaneous revascularization in patients with symptomatic femoropopliteal lesions from 200 to 460 mm in length with chronic total occlusions (100 to 425 mm) or diffuse stenosis > 70% who may be considered suboptimal candidates for surgical or alternative endovascular treatments.

The Detour system, or any of its components, is not for use in the coronary and cerebral vasculature, advised the company.